arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Bristol-Myers Squibb Company

BMY Health Care Biotechnology: Pharmaceutical Preparations
$63.00
▲ +2.1% Today
as of Oct 22, 16:46 ET
Last 30 days -1.72% Sep 14 → Oct 22
$56.08 $58.23 $60.38 $62.54 $64.69 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$61.46
High
$63.59
Low
$61.04
Volume
$15M
Avg Vol
$13M
Mkt Cap
$122.0B
P/E (TTM)
14.90
Beta
—
52w High
$68.64
52w Low
$42.52
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 25 items

mixed ▲ 3 ● 21 ▼ 1
Oct 21 · 13:00 Zacks neutral
Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio?
Oct 20 · 16:31 Insider Monkey neutral
Bristol Myers (BMY) Has New Cancer Wins. Can They Offset the Patent Cliff?
Oct 20 · 12:28 Insider Monkey neutral
Bristol Myers vs. Eli Lilly: Is BMY’s Deep Valuation Discount Hiding an Opportunity?
▸ Show all 25 press releases & news Free account →

BMY earnings at a glance

Bristol-Myers Squibb Company (BMY) is scheduled to report earnings on Thursday, October 29, 2026 before the market opens — in 6 days. Analysts expect earnings per share of $1.69, compared with $1.63 in the same quarter last year (+4%). The options market is pricing a move of about ±7.4% after the report, a range of roughly $58.31 to $67.69 from today's $63.00. Over its last 6 reports the stock rose the next day 5 times and fell 1, moving ±4.1% on average; after the most recent report on Jul 30, 2026 it moved +2.8%. That means options currently expect more movement than BMY has typically delivered. BMY beat the consensus EPS estimate in 6 of its last 6 reported quarters. Implied volatility is currently 38%. The share price of $63.00 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$43
$69
78% of range
Avg surprise (last 6)
+18.9%
Avg reaction (last 6)
+2.2%
83% positive
Latest IV / EM
38%
EM ±7.4% · $60 · Oct 30

Earnings trends

EPS — actual vs estimate Actual Estimate
$-5.89$-3.91$-1.92$0.06$2.04 Actual $1.07Actual $0.99Actual $0.93Actual $-5.89Actual $0.83Actual $0.60Actual $1.80Est $1.51Actual $1.46Est $1.07Actual $1.63Est $1.48Actual $1.26Est $1.15Actual $1.58Est $1.44Actual $2.04Est $1.59 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258K8KJun/2026
Revenue vs Net Income Revenue Net income
$0$3.4B$6.8B$10.2B$13.6B Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu Jul 30, 2026Jun/2026 $2.04 $1.59 +28.3% +8.9% +2.8% earnings
Thu Apr 30, 20268K 2026-04-30 $1.58 $1.44 +9.7% — +5.2% earnings
Thu Feb 5, 20268K 2026-02-05 $1.26 $1.15 +9.6% — +3.3% earnings
Thu Oct 30, 2025Sep/2025 $1.63 $1.48 +10.1% — +7.1% earnings
Thu Jul 31, 2025Jun/2025 $1.46 $1.07 +36.5% — -5.8% earnings
Thu Apr 24, 2025Mar/2025 $1.80 $1.51 +19.2% — +0.3% earnings
Mon Sep 30, 2024Sep 2024 $0.60 — — — — financials
Sun Jun 30, 2024Jun 2024 $0.83 — — — — financials
Sun Mar 31, 2024Mar 2024 $-5.89 — — — — financials
Sat Sep 30, 2023Sep 2023 $0.93 — — — — financials
Fri Jun 30, 2023Jun 2023 $0.99 — — — — financials
Fri Mar 31, 2023Mar 2023 $1.07 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Oct 29, 2026Sep/2026BMO $1.69$1.63 +3.7%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$12.97B$11.49B—$12.22B$12.27B$11.20B—$11.89B
Cost of revenue$3.73B$3.42B—$3.44B$3.37B$3.03B—$2.96B
Gross profit————————
Operating income————————
Net income$3.32B$2.68B—$2.20B$1.31B$2.46B—$1.21B
EPS (diluted)$1.62$1.31—$1.08$0.64$1.20—$0.60

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$8.72B$9.57B$10.21B$15.73B$12.60B$10.88B$10.35B$7.89B
Inventory$2.74B$2.76B$2.69B$2.76B$2.74B$2.67B$2.56B$3.33B
Total current assets$28.58B$27.21B$29.39B$35.63B$33.22B$30.78B$29.78B$28.07B
Total assets$87.63B$86.48B$90.04B$96.89B$94.68B$92.43B$92.60B$93.67B
Long-term debt$42.09B$42.15B$42.85B$44.47B$44.47B$46.16B$47.60B$48.67B
Total liabilities$65.31B$66.37B$71.53B$78.29B$77.19B$74.98B$76.22B$76.47B
Total equity$22.32B$20.07B$18.47B$18.55B$17.43B$17.39B$16.34B$17.14B

Implied volatility — last 90 days

24%34%45%55%65% Jun 07 — IV 38% · EM ±3.5%Jun 08 — IV 31% · EM ±2.6%Jun 09 — IV 33% · EM ±2.4%Jun 10 — IV 35% · EM ±2.0%Jun 11 — IV 38% · EM ±1.6%Jun 15 — IV 32% · EM ±2.3%Jun 16 — IV 31% · EM ±1.9%Jun 17 — IV 37% · EM ±1.5%Jun 19 — IV 27% · EM ±3.0%Jun 22 — IV 31% · EM ±2.6%Jun 23 — IV 30% · EM ±2.2%Jun 24 — IV 30% · EM ±1.8%Jun 25 — IV 41% · EM ±1.7%Jun 29 — IV 32% · EM ±7.5%Jun 30 — IV 33% · EM ±7.6%Jul 01 — IV 32% · EM ±7.4%Jul 02 — IV 31% · EM ±7.0%Jul 03 — IV 32% · EM ±7.0%Jul 06 — IV 33% · EM ±6.9%Jul 07 — IV 33% · EM ±6.7%Jul 08 — IV 33% · EM ±6.7%Jul 09 — IV 33% · EM ±6.5%Jul 10 — IV 32% · EM ±6.2%Jul 13 — IV 37% · EM ±6.5%Jul 14 — IV 48% · EM ±8.3%Jul 15 — IV 36% · EM ±6.1%Jul 16 — IV 38% · EM ±6.2%Jul 17 — IV 40% · EM ±6.2%Jul 20 — IV 42% · EM ±5.8%Jul 21 — IV 42% · EM ±5.6%Jul 22 — IV 40% · EM ±5.0%Jul 23 — IV 42% · EM ±5.0%Jul 24 — IV 44% · EM ±4.9%Jul 27 — IV 57% · EM ±4.7%Jul 28 — IV 60% · EM ±4.4%Jul 29 — IV 66% · EM ±3.9%Jul 30 — IV 33% · EM ±1.4%Aug 03 — IV 40% · EM ±3.4%Aug 04 — IV 55% · EM ±3.9%Aug 05 — IV 36% · EM ±2.1%Aug 06 — IV 36% · EM ±1.5%Aug 10 — IV 28% · EM ±2.4%Aug 11 — IV 25% · EM ±1.8%Aug 12 — IV 30% · EM ±1.8%Aug 13 — IV 30% · EM ±1.3%Aug 17 — IV 28% · EM ±2.4%Aug 18 — IV 33% · EM ±2.4%Aug 19 — IV 37% · EM ±2.2%Aug 20 — IV 61% · EM ±2.6%Aug 24 — IV 30% · EM ±2.5%Aug 25 — IV 36% · EM ±2.6%Aug 26 — IV 31% · EM ±1.9%Aug 27 — IV 30% · EM ±1.2%Aug 31 — IV 26% · EM ±2.2%Sep 01 — IV 27% · EM ±1.9%Sep 02 — IV 31% · EM ±1.8%Sep 03 — IV 31% · EM ±1.3%Sep 07 — IV 28% · EM ±2.3%Sep 08 — IV 27% · EM ±2.0%Sep 09 — IV 28% · EM ±1.7%Sep 10 — IV 31% · EM ±1.3%Sep 14 — IV 28% · EM ±2.3%Sep 15 — IV 31% · EM ±2.2%Sep 16 — IV 30% · EM ±1.8%Sep 17 — IV 26% · EM ±1.1%Sep 21 — IV 26% · EM ±2.2%Sep 22 — IV 32% · EM ±2.3%Sep 23 — IV 33% · EM ±1.9%Sep 24 — IV 41% · EM ±1.7%Sep 28 — IV 34% · EM ±8.1%Sep 29 — IV 35% · EM ±8.2%Sep 30 — IV 39% · EM ±8.9%Oct 01 — IV 35% · EM ±8.0%Oct 02 — IV 36% · EM ±8.0%Oct 06 — IV 36% · EM ±7.3%Oct 07 — IV 39% · EM ±7.8%Oct 08 — IV 38% · EM ±7.4%

Sector peers

VRTX
Vertex Pharmaceuticals Incorporated
$128.2B $535.17+4.0%
SNY
Sanofi
$98.0B $41.96+1.4%
REGN
Regeneron Pharmaceuticals, Inc.
$76.4B $819.09+1.4%
NVO
Novo Nordisk A/S
$169.4B $39.43+0.2%
ABT
Abbott Laboratories
$170.8B $102.51+0.1%
TEVA
Teva Pharmaceutical Industries Limited
$45.7B $40.21-1.6%

BMY earnings FAQ

When is BMY's next earnings date?

Bristol-Myers Squibb Company is expected to report on October 29, 2026, before the market opens.

What is BMY's expected move for earnings?

Options currently price a move of about ±7.4%, or $4.69 per share either way from $63.00.

How does BMY stock usually react to earnings?

Across the last 6 reports the average next-day move was ±4.1%, up 5 times and down 1 times.

What EPS are analysts expecting from Bristol-Myers Squibb Company?

The consensus estimate is $1.69 per share, versus $1.63 a year ago.

What is BMY's implied volatility?

BMY's at-the-money implied volatility is about 38% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in